In this edition of our NCIA Committee Insights series originally aired on Wednesday, July 14, 2021 we were joined by members of our Cannabis Manufacturing Committee for a discussion about how terpene limits, both in edibles and inhalables, as well as vapor products can be manufactured so as to place them as low as reasonably possible on the risk continuum.
With years of research and study ahead of us, it wouldn’t be appropriate to call many manufactured cannabis products “safe.” But that doesn’t mean we need to stop selling products until all the data is in. We know enough now to make manufactured products safer than the alternatives, in other words, provide a harm reduction benefit.
Presentation Slide Deck: https://bit.ly/3xMuBWC
• Principles of harm reduction and risk continuum
• Latest thinking in terpene limits (edibles and inhalables)
• Latest thinking in vapor hardware configuration and testing
Lior Chatow, Research And Development Manager, Eybna
Ramon Alarcon, Founder + CEO, Wellness Insight Technologies, Inc.
Arnaud Dumas de Rauly, Co-Founder & CEO, Blinc Group